{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:05:29Z","timestamp":1785787529491,"version":"3.56.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1097\/01.mol.0000137225.46654.4d","type":"journal-article","created":{"date-parts":[[2004,7,8]],"date-time":"2004-07-08T04:04:51Z","timestamp":1089259491000},"page":"387-392","source":"Crossref","is-referenced-by-count":28,"title":["Phenotypes, genotypes and response to statin therapy"],"prefix":"10.1097","volume":"15","author":[{"given":"Muriel J","family":"Caslake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J","family":"Packard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"R2-3-20210205","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.97.15.1440","article-title":"","volume":"97","year":"1998","journal-title":"Circulation"},{"key":"R3-3-20210205","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/01.CIR.97.15.1446","article-title":"Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial.","volume":"97","author":"Sacks","year":"1998","journal-title":"Circulation"},{"key":"R4-3-20210205","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0002-9149(02)02599-7","article-title":"Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS).","volume":"90","author":"Streja","year":"2002","journal-title":"Am J Cardiol"},{"key":"R5-3-20210205","doi-asserted-by":"crossref","first-page":"66B","DOI":"10.1016\/S0002-9149(98)00041-1","article-title":"Comparison of statins in hypertriglyceridemia.","volume":"81","author":"Stein","year":"1998","journal-title":"Am J Cardiol"},{"key":"R6-3-20210205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00041433-200204000-00001","article-title":"The APOE locus and the pharmacogenetics of lipid response.","volume":"13","author":"Ordovas","year":"2002","journal-title":"Curr Opin Lipidol"},{"key":"R7-3-20210205","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00041433-199706000-00003","article-title":"3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion.","volume":"8","author":"Huff","year":"1997","journal-title":"Curr Opin Lipidol"},{"key":"R8-3-20210205","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0021-9150(02)00052-7","article-title":"Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.","volume":"164","author":"Forster","year":"2002","journal-title":"Atherosclerosis"},{"key":"R9-3-20210205","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1210\/jcem.87.5.8455","article-title":"Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.","volume":"87","author":"Chan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-3-20210205","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2337\/diabetes.52.3.803","article-title":"Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.","volume":"52","author":"Watts","year":"2003","journal-title":"Diabetes"},{"key":"R11-3-20210205","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1194\/jlr.M300309-JLR200","article-title":"Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.","volume":"45","author":"Bilz","year":"2004","journal-title":"J Lipid Res"},{"key":"R12-3-20210205","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1124\/jpet.103.048991","article-title":"Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes.","volume":"306","author":"Ouguerram","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R13-3-20210205","doi-asserted-by":"crossref","first-page":"14728","DOI":"10.1016\/S0021-9258(17)42663-9","article-title":"Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins.","volume":"259","author":"Bradley","year":"1984","journal-title":"J Biol Chem"},{"key":"R14-3-20210205","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0006-291X(86)80118-8","article-title":"Apolipoprotein E-mediated binding of hypertriglyceridemic very low density lipoproteins to isolated low density lipoprotein receptors detected by ligand blotting.","volume":"139","author":"Brown","year":"1986","journal-title":"Biochem Biophys Res Commun"},{"key":"R15-3-20210205","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1172\/JCI111708","article-title":"Roles of apolipoproteins B and E in the cellular binding of very low density lipoproteins.","volume":"75","author":"Krul","year":"1985","journal-title":"J Clin Invest"},{"key":"R16-3-20210205","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1161\/01.ATV.10.6.1088","article-title":"Abnormal composition of hypertriglyceridemic very low density lipoprotein determines abnormal cell metabolism.","volume":"10","author":"Sehayek","year":"1990","journal-title":"Arteriosclerosis"},{"key":"R17-3-20210205","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0022-2275(20)32065-4","article-title":"Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.","volume":"41","author":"Packard","year":"2000","journal-title":"J Lipid Res"},{"key":"R18-3-20210205","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.atherosclerosis.2003.08.025","article-title":"Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia.","volume":"171","author":"Caslake","year":"2003","journal-title":"Atherosclerosis"},{"key":"R19-3-20210205","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0021-9150(03)00106-0","article-title":"Cholesterol synthesis and absorption in coronary patients with lipid triad and isolated high LDL cholesterol in a 4S subgroup.","volume":"168","author":"Miettinen","year":"2003","journal-title":"Atherosclerosis"},{"key":"R20-3-20210205","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-2796.1999.00548.x","article-title":"Postprandial lipoprotein metabolism and atherosclerosis.","volume":"246","author":"Karpe","year":"1999","journal-title":"J Intern Med"},{"key":"R21-3-20210205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2003.07.006","article-title":"Normalization of daytime triglyceridemia by simvastatin in fasting normotriglyceridemic patients with premature coronary sclerosis.","volume":"171","author":"van Wijk","year":"2003","journal-title":"Atherosclerosis"},{"key":"R22-3-20210205","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0026-0495(03)00281-6","article-title":"Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease.","volume":"52","author":"Dane-Stewart","year":"2003","journal-title":"Metabolism"},{"key":"R23-3-20210205","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1194\/jlr.M300011-JLR200","article-title":"Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients.","volume":"44","author":"Parhofer","year":"2003","journal-title":"J Lipid Res"},{"key":"R24-3-20210205","first-page":"4224","article-title":"Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects.","volume":"85","author":"Parhofer","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R25-3-20210205","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1253\/circj.67.866","article-title":"Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients.","volume":"67","author":"Sakabe","year":"2003","journal-title":"Circ J"},{"key":"R26-3-20210205","first-page":"854","article-title":"2 diabetes (UKPDS Study Group 34). UK Prospective Diabetes Study (UKPDS) Group.","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"R27-3-20210205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.amjcard.2003.09.008","article-title":"Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.","volume":"93","author":"Schaefer","year":"2004","journal-title":"Am J Cardiol"},{"key":"R28-3-20210205","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.atherosclerosis.2003.08.030","article-title":"Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia.","volume":"171","author":"Westphal","year":"2003","journal-title":"Atherosclerosis"},{"key":"R29-3-20210205","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R30-3-20210205","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet Med"},{"key":"R31-3-20210205","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1161\/01.CIR.0000080897.52664.94","article-title":"Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.","volume":"108","author":"Sattar","year":"2003","journal-title":"Circulation"},{"key":"R32-3-20210205","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/01.CIR.98.23.2513","article-title":"Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.","volume":"98","author":"Goldberg","year":"1998","journal-title":"Circulation"},{"key":"R33-3-20210205","first-page":"1670","article-title":"Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.","volume":"25","author":"Hunninghake","year":"2003","journal-title":"ClinTher"},{"key":"R34-3-20210205","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.ijo.0802287","article-title":"Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome.","volume":"27","author":"Watts","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R35-3-20210205","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1053\/meta.2002.33339","article-title":"Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.","volume":"51","author":"Chan","year":"2002","journal-title":"Metabolism"},{"key":"R36-3-20210205","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/circ.105.1.2","article-title":"On evolutionary biology, inflammation, infection, and the causes of atherosclerosis.","volume":"105","author":"Ridker","year":"2002","journal-title":"Circulation"},{"key":"R37-3-20210205","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"},{"key":"R38-3-20210205","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1464-5491.2003.00993.x","article-title":"Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose.","volume":"20","author":"Costa","year":"2003","journal-title":"Diabet Med"},{"key":"R39-3-20210205","doi-asserted-by":"crossref","first-page":"12E","DOI":"10.1016\/S0002-9149(02)03383-0","article-title":"High-density lipoprotein subpopulations in pathologic conditions.","volume":"91","author":"Asztalos","year":"2003","journal-title":"Am J Cardiol"},{"key":"R40-3-20210205","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.0000103624.14436.4B","article-title":"Inflammatory\/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.","volume":"108","author":"Ansell","year":"2003","journal-title":"Circulation"},{"key":"R41-3-20210205","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0002-8703(03)00440-X","article-title":"Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).","volume":"146","author":"Ballantyne","year":"2003","journal-title":"Am Heart J"},{"key":"R42-3-20210205","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0002-9149(03)00318-7","article-title":"Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.","volume":"91","author":"Capuzzi","year":"2003","journal-title":"Am J Cardiol"},{"key":"R43-3-20210205","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.amjcard.2003.08.078","article-title":"CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.","volume":"93","author":"Kajinami","year":"2004","journal-title":"Am J Cardiol"},{"key":"R44-3-20210205","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1194\/jlr.M300278-JLR200","article-title":"ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin.","volume":"45","author":"Kajinami","year":"2004","journal-title":"J Lipid Res"},{"key":"R45-3-20210205","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0021-9150(03)00094-7","article-title":"Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy.","volume":"168","author":"Lahoz","year":"2003","journal-title":"Atherosclerosis"},{"key":"R46-3-20210205","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199801083380203","article-title":"The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.","volume":"338","author":"Kuivenhoven","year":"1998","journal-title":"N Engl J Med"},{"key":"R47-3-20210205","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0002-8703(03)00501-5","article-title":"The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease.","volume":"146","author":"Carlquist","year":"2003","journal-title":"Am Heart J"},{"key":"R48-3-20210205","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.ehj.2003.07.001","article-title":"A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study.","volume":"24","author":"Freeman","year":"2003","journal-title":"Eur Heart J"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.mol.0000137225.46654.4d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:10:04Z","timestamp":1785784204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00041433-200408000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mol.0000137225.46654.4d","relation":{},"ISSN":["0957-9672"],"issn-type":[{"value":"0957-9672","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}